- Home
- BAOS vs TIVC Comparison
BAOS vs TIVC Comparison
Compare BAOS & TIVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAOS | TIVC |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.6M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BAOS | TIVC |
|---|---|---|
| Price | $3.10 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 76.5K | ★ 222.5K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.98 | $0.75 |
| 52 Week High | $5.40 | $5.60 |
Technical Indicators
Market Signals| Indicator | BAOS | TIVC |
|---|---|---|
| Relative Strength Index (RSI) | 53.32 | 69.31 |
| Support Level | $2.45 | $0.79 |
| Resistance Level | $3.64 | $2.70 |
| Average True Range (ATR) | 0.37 | 0.11 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 43.05 | 100.00 |
Price Performance
Historical ComparisonAbout BAOS Baosheng Media Group Holdings
Baosheng Media Group Holdings Ltd is a China-based online marketing solution provider. The company provides internet marketing, short-video and V-log marketing, content production and operation, e-commerce marketing, data platform services, and AI technology-related services. It also offers customized marketing solutions and channel marketing services through partnerships with internet platforms such as Tencent, Alibaba, ByteDance, and Kuaishou.
About TIVC Tivic Health Systems Inc.
Tivic Health Systems Inc is a late-stage biopharmaceutical company focused on the development of biologics, with its lead product candidate, Entolimod, a TLR5 agonist, being developed for acute radiation syndrome and oncology-related indications. The company operates through two segments: a biopharma segment focused on product development and commercialization, and a contract development and manufacturing organization (CDMO) segment providing manufacturing and development services through its subsidiary.